Emerging resistance of anaerobic bacteria to antimicrobial agents in South Korea

Kyungwon Lee, Yunsop Chong, Seok Hoon Jeong, Xue Song Xu, Oh Hun Kwon

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

In previous studies, Bacteroides fragilis group organisms isolated from Korean patients were more frequently resistant to various antimicrobial agents, including clindamycin, than were isolates in other countries. A recent report of increased resistance of Peptostreptococcus species prompted us to include such isolates in a study of antimicrobial susceptibility. Anaerobes isolated in 1994 at a tertiary care hospital in Seoul were tested by an agar dilution method. None of the B. fragilis group organisms were resistant to imipenem, cefoxitin, chloramphenicol, or metronidazole. However, 6.7% were resistant to ampicillin/sulbactam, 20.2% to cefotetan, 30.3% to piperacillin, 48.3% to cefotaxime, and 42.7% to clindamycin. Almost all of the Clostridium perfringens isolates were susceptible to all of the agents tested, except tetracycline. Peptostreptococcus isolates were susceptible to piperacillin, cefotaxime, and imipenem, while 7.4% were resistant to penicillin G, cefotetan, and metronidazole, and 25.9% were resistant to clindamycin. The isolates resistant to penicillin G, cefotetan, and metronidazole were identified as Peptostreptococcus anaerobius. In conclusion, besides the well-known high rate of resistance of B. fragilis group organisms to clindamycin, the emergence of resistance of Peptostreptococcus species isolates to β-lactam drugs has become obvious in Korea.

Original languageEnglish
Pages (from-to)S73-S77
JournalClinical Infectious Diseases
Volume23
Issue numberSUPPL. 1
DOIs
Publication statusPublished - 1996

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Emerging resistance of anaerobic bacteria to antimicrobial agents in South Korea'. Together they form a unique fingerprint.

  • Cite this